RedHill Biopharma announces new USPTO patent covering Talicia through 2034

RedHill Biopharma announced the issue of a new U.S. patent covering Talicia as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori infection. Talicia is a first-line therapy prescribed by U.S. gastroenterologists for H. pylori infection, which affects approximately 35% of the U.S. adult population and this patent is expected to provide protection for Talicia until February 12, 2034. “Talicia is the only FDA-approved rifabutin-containing all-in-one therapy for the eradication of H. pylori. Its components and formulation are optimized to provide patients with the right medications for successful H. pylori eradication with an optimized resistance profile, which is significant in the face of growing microbial resistance to clarithromycin-based regimens,” said Patricia Anderson, RedHill’s Senior Vice President of Regulatory Affairs.